Holen Sie sich die Stockscreener-App
35.35
2.85%
0.98
Schlusskurs vom Vortag:
$34.37
Offen:
$34.37
24-Stunden-Volumen:
606.16K
Relative Volume:
1.01
Marktkapitalisierung:
$2.00B
Einnahmen:
$32.87M
Nettoeinkommen (Verlust:
$674.31M
KGV:
3.1118
EPS:
11.36
Netto-Cashflow:
$-330.11M
1W Leistung:
+8.07%
1M Leistung:
+8.34%
6M Leistung:
+11.02%
1J Leistung:
-15.93%
1-Tages-Spanne:
$34.03
$35.85
1-Wochen-Bereich:
$32.59
$35.85
52-Wochen-Spanne:
$23.41
$62.58
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Firmenname
Agios Pharmaceuticals Inc
Sektor
Branche
Telefon
617-649-8600
Adresse
88 SIDNEY STREET, CAMBRIDGE, MA
Vergleichen Sie AGIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
35.35 | 2.00B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-09-27 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-17 | Hochstufung | Goldman | Sell → Neutral |
| 2022-07-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Equal Weight |
| 2019-11-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-02-15 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Eingeleitet | Leerink Partners | Mkt Perform |
| 2018-05-23 | Eingeleitet | Citigroup | Buy |
| 2018-04-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-02-15 | Bestätigt | Needham | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-08-10 | Bestätigt | Needham | Buy |
| 2017-08-08 | Bestätigt | SunTrust | Buy |
| 2017-08-02 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Herabstufung | Janney | Buy → Neutral |
| 2017-01-17 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Eingeleitet | Needham | Buy |
| 2016-06-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Bestätigt | SunTrust | Buy |
Alle ansehen
Agios Pharmaceuticals Inc Aktie (AGIO) Neueste Nachrichten
Agios Pharmaceuticals, Inc. (AGIO) Backed by TD Cowen for Mitapivat’s Market Potential - MSN
Agios Pharma Increases Shares in Stock Incentive Plan - TipRanks
H.C. Wainwright Maintains a Buy Rating on Agios Pharmaceuticals (AGIO), Reduces PT - MSN
Agios' PYRUKYND Faces FDA Review In SeptemberExpansion Opportunity Ahead? - RTTNews
10 Best NASDAQ Stocks Under $50 to Buy - Insider Monkey
TD Cowen reiterates buy rating on Agios stock ahead of key trial data - Investing.com Canada
Agios Pharmaceuticals Sees Shift in Fund Positioning Russell 1000 - Kalkine Media
10 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey
Agios Pharmaceuticals: A More Compelling Valuation (NASDAQ:AGIO) - Seeking Alpha
Avanzanite annuncia la partnership paneuropea con Agios per lanciare mitapivat nelle malattie ematologiche rare - standard-journal.com
Avanzanite annonce un partenariat paneuropéen avec Agios pour le lancement de PYRUKYND® dans les maladies rares du sang - Eagle-Tribune
Avanzanite gibt europaweite Partnerschaft mit Agios zur Einführung von PYRUKYND® bei seltenen Blutgerinnungsstörungen bekannt - standard-journal.com
Cantor Fitzgerald Predicts AGIO FY2026 Earnings - Defense World
Agios Pharma stock target cut to $56 by H.C. Wainwright - Investing.com Canada
Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders - afp.com
Agios Pharmaceuticals (AGIO) Target Price Revised Amid New Europ - GuruFocus
Agios Pharmaceuticals (AGIO) Target Price Revised Amid New European Deal | AGIO Stock News - GuruFocus
Agios at Goldman Sachs Conference: Strategic Growth in Rare Diseases By Investing.com - Investing.com Canada
Transcript : Agios Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - MarketScreener
Agios stock rises on European distribution deal By Investing.com - Investing.com South Africa
Agios stock rises on European distribution deal - Investing.com Australia
Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders | AGIO Stock News - GuruFocus
California State Teachers Retirement System Trims Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND in Rare Blood Disorders - Business Wire
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $56.50 Average Target Price from Analysts - Defense World
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock Holdings Lowered by Millennium Management LLC - Defense World
Nuveen Asset Management LLC Cuts Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
Ameriprise Financial Inc. Sells 34,140 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
When the Price of (AGIO) Talks, People Listen - news.stocktradersdaily.com
Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025 | AGIO Stock News - GuruFocus
Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025 - The Manila Times
Agios Pharmaceuticals Showcases Rare Disease Breakthroughs at Goldman Sachs Healthcare Conference - Stock Titan
BNP Paribas Financial Markets Sells 2,242 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
What is Zacks Research’s Estimate for AGIO Q2 Earnings? - Defense World
Agios Pharmaceuticals’ SWOT analysis: promising drug pipeline drives stock outlook By Investing.com - Investing.com South Africa
Agios Pharmaceuticals’ SWOT analysis: promising drug pipeline drives stock outlook - Investing.com Canada
Bank of America Corp DE Raises Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded to Sell Rating by StockNews.com - Defense World
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates - MSN
Analysts Update Their Estimates For Agios Pharmaceuticals Inc - Stocksregister
Agios pharmaceuticals outlines key catalysts for PYRUKYND pipeline in 2025 - MSN
Agios Pharma (AGIO) Gets a Buy from Bank of America Securities - The Globe and Mail
Beta thalassemia Market: Epidemiology, Therapies, Companies, - openPR.com
Sickle cell disease Market: Epidemiology, Therapies, - openPR.com
Agios Pharmaceuticals at Bank of America 2025 Healthcare Conference: Strategic Pipeline Advances - Investing.com Canada
Agios to Highlight Pyruvate Kinase Activation Portfolio with New - GuruFocus
Agios Pharmaceuticals (AGIO) Highlights Promising Data at EHA 20 - GuruFocus
Agios Pharmaceuticals (AGIO) Highlights Promising Data at EHA 2025 | AGIO Stock News - GuruFocus
Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress - The Manila Times
New Phase 3 Trial Data: Agios Blood Disorder Treatment Shows Promise in Children and Adults with Rare Diseases - Stock Titan
Northern Trust Corp Purchases 5,372 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
Finanzdaten der Agios Pharmaceuticals Inc-Aktie (AGIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Agios Pharmaceuticals Inc-Aktie (AGIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Burns James William | Chief Legal Officer |
Jun 24 '25 |
Option Exercise |
0.00 |
6,000 |
0 |
31,449 |
| Burns James William | Chief Legal Officer |
Jun 24 '25 |
Sale |
33.54 |
2,799 |
93,878 |
28,650 |
| Gheuens Sarah | Chief Medical Officer |
Jun 24 '25 |
Option Exercise |
0.00 |
6,000 |
0 |
59,897 |
| Gheuens Sarah | Chief Medical Officer |
Jun 24 '25 |
Sale |
33.54 |
2,909 |
97,568 |
56,988 |
| Jones Cecilia | Chief Financial Officer |
Jun 24 '25 |
Option Exercise |
0.00 |
6,000 |
0 |
31,829 |
| Jones Cecilia | Chief Financial Officer |
Jun 24 '25 |
Sale |
33.54 |
1,780 |
59,701 |
30,049 |
| Milanova Tsveta | Chief Commercial Officer |
Jun 24 '25 |
Option Exercise |
0.00 |
6,000 |
0 |
28,892 |
| Milanova Tsveta | Chief Commercial Officer |
Jun 24 '25 |
Sale |
33.54 |
2,770 |
92,906 |
26,122 |
| Goff Brian | Chief Executive Officer |
Jun 24 '25 |
Option Exercise |
0.00 |
38,277 |
0 |
118,151 |
| Goff Brian | Chief Executive Officer |
Jun 24 '25 |
Sale |
33.54 |
18,700 |
627,198 |
105,401 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):